Better Therapeutics, Inc. BTTX
0.00
0.00
NaN
as of 25 Sep
- Market cap
- $850.0K
- P/E
- 0.0×
Follow BTTX
| Dec '17 | Dec '20 | Dec '21 | Dec '22 | |
|---|---|---|---|---|
P/E ratio |
— | 0.00 | — | — |
P/S ratio |
— | 0.00 | — | — |
P/FCF ratio |
— | 0.00 | — | — |
P/Operating CF |
— | 0.00 | — | — |
P/B ratio |
— | 0.00 | — | — |
Price to Tangible BV |
— | 0.00 | — | — |
EV/Sales |
— | 0.00 | — | — |
EV/EBITDA |
— | 0.00 | — | — |
EV/Operating CF |
— | 0.00 | — | — |
EV/FCF |
— | 0.00 | — | — |
Quick Ratio |
— | 0.20 | 8.57 | 1.17 |
Current Ratio |
— | 0.76 | 9.56 | 1.37 |
Net Debt/EBITDA |
— | (0.09) | 1.07 | 0.02 |
Debt/Assets |
0.00% | 10.99% | 18.65% | 64.86% |
Debt/Equity |
— | (0.10) | 0.26 | (16.55) |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.73 | 0.76 | 0.73 |
Capex/Depreciation |
— | (30.73) | (0.66) | (0.43) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 |
| — | (52.69%) | (269.24%) | (221.99%) | |
| — | (247.19%) | (140.67%) | (107.60%) | |
ROIC |
— | 0.00% | (337.52%) | 0.00% |
Return on Tangible Assets |
— | 12,940.98% | (99.35%) | (783.76%) |
Average Days of Receivables |
— | 0.00 | — | — |
Research and Development Expense of Revenue |
— | 45,750.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 33,387.50% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 2,912.50% | 0.00% | 0.00% |
Graham Net Nets |
— | 0.00 | — | — |
Graham Number |
— | 0.00 | — | — |
Earnings Yield |
— | (68.25%) | — | — |
Free Cash Flow Yield |
— | 0.00% | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.58) | (2.37) | (1.23) |
Capex per Share |
— | (0.23) | (0.08) | (0.05) |
Free Cash Flow per Share |
— | (0.81) | (2.46) | (1.28) |
Cash per Share |
— | 0.01 | 3.12 | 0.67 |
Shareholders Equity per Share |
— | (0.68) | 2.83 | (0.04) |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (0.68) | 2.83 | (0.04) |
Free Cash Flow |
— | (8.08) | (31.89) | (30.11) |
Working Capital |
— | (0.15) | 40.52 | 4.95 |
Capital Expenditures |
— | (2.30) | (1.07) | (1.18) |
Net Current Asset Value |
— | (12.68) | 31.01 | (5.40) |
EV/EBIT |
— | 0.00 | — | — |
Capex to Sales |
— | 288.13 | 0.00 | 0.00 |
Net Profit Margin |
— | (98,675.00%) | 0.00% | 0.00% |
Price to Operating Income |
— | 0.00 | — | — |
| Other line items | ||||
Depreciation/Fixed assets |
— | 0.84 | 19.74 | 22.55 |
Cash ROIC |
— | 98.82% | (35.60%) | (97.75%) |
Accounts Receivable Turnover |
— | 0.00 | — | — |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | 0.00 |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 |
Average Payables |
— | 1.02 | 1.02 | 2.28 |
Average Assets |
— | 3.19 | 28.67 | 36.95 |
Average Common Equity |
— | 14.98 | 14.98 | 17.91 |
Columns are period end dates